Fig 1.
Patient demographics and baseline characteristics*.
*Table designed according to the IFM trial for easier comparison [4] **statistically significant difference at p < 0.05.
Fig 2.
Rates of response to treatment by group in the response-evaluable population.
*ORR = treatment response PR and better, **CBR = treatment response MR and better.
Fig 3.
Rates of adverse events in SC and IV aplication routes of bortezomib.
Fig 4.
Comparison of the incidence of PN in patients treated with IV and SC bortezomib in the IFM trial and CMG analysis.